WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial